Floatz logo

Benmelstobart

Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

87 Active assets in the Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL) cohort.

Asset / SponsorPhaseRating
Ifosfamide
David Bond, MD
Phase 4BBB
Inno-206
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
Inno-206
University of Washington
Phase 4BBB

View all 50 →

Same molecule, other indications

Benmelstobart is also rated in:

small cell lung carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
AnlotinibDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →